Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PuraPharmHKSE:01498 23 EV-to-FCF is 18.87 as of Aug. 20, 2026, which is 56% above its 10-year median of 12.08. GuruFocus rates HKSE:01498 with a GF Score™ of 23/100 and a GF Value™ of HK$0.51 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 558 Drug Manufacturers companies, PuraPharm ranks better than 54.12% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, PuraPharm's Enterprise Value is HK$484.8 Mil.
PuraPharm's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was HK$25.7 Mil. Therefore, PuraPharm's EV-to-FCF for today is 18.87.
The historical rank and industry rank for PuraPharm's EV-to-FCF or its related term are showing as below:
HKSE:01498'
s EV-to-FCF Range Over the Past 10 Years
Min: -52.67 Med: 12.08 Max: 42.55
Current: 18.87
During the past 12 years, the highest EV-to-FCF of PuraPharm was 42.55. The lowest was -52.67. And the median was 12.08.
HKSE:01498's EV-to-FCF is ranked better than 54.12% of 558
companies
in the Drug Manufacturers industry
Industry Median: 21.27
vs HKSE:01498: 18.87
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
PuraPharm's share price for today is HK$0.28.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. PuraPharm's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-0.084.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
PuraPharm EV-to-FCF Related Terms
PuraPharm EV-to-FCF Historical Data
* Premium members only.
The historical data trend for PuraPharm's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, PuraPharm's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PuraPharm EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PuraPharm's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where PuraPharm's EV-to-FCF falls into.
PuraPharm's current Enterprise Value is HK$484.8 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. PuraPharm's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was HK$25.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PuraPharm (HKSE:01498) has a EV-to-FCF of 18.87 as of Aug. 20, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on PuraPharm and its competitors. This is 56% above median its historical median of 12.08. According to the industry distribution chart, PuraPharm ranks #256 out of 558 companies in the Drug Manufacturers industry, placing it in the top 45.9%.
Is PuraPharm's EV-to-FCF too high?
PuraPharm's current EV-to-FCF of 18.87 is 56% above median its 10-year median of 12.08. The Drug Manufacturers industry median EV-to-FCF is 21.27. PuraPharm's value of 18.87 is 11.3% below this industry median. Based on the distribution chart, PuraPharm ranks #256 out of 558 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, PuraPharm has a GF Score™ of 23/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does PuraPharm's EV-to-FCF compare to ZTS?
According to the Drug Manufacturers industry distribution chart, PuraPharm ranks #256 out of 558 companies for EV-to-FCF. This puts PuraPharm in the upper half of its industry. The industry median EV-to-FCF is 21.27. PuraPharm's value of 18.87 is 11.3% below this benchmark. While the company's 10-year median is 12.08 vs. the industry median of 21.27, PuraPharm has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 21.27, based on 558 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PuraPharm's current EV-to-FCF of 18.87 is 11.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on PuraPharm and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 21.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PuraPharm's current EV-to-FCF is 18.87, which is 56% above median its own 10-year median of 12.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PuraPharm stock overvalued right now?
Based on GuruFocus' analysis, PuraPharm (HKSE:01498) is currently considered Possible Value Trap. The stock's GF Value™ is HK$0.51, compared to a current price of HK$0.28 — trading 45.1% below its estimated fair value. The current EV-to-FCF is 18.87, which is 56% above median its 10-year median of 12.08 and 11.3% below the Drug Manufacturers industry median of 21.27. PuraPharm's overall GF Score™ is 23/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For PuraPharm (HKSE:01498), the current EV-to-FCF is 18.87 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PuraPharm (HKSE:01498) Overvalued in 2026?
Based on GuruFocus' analysis, PuraPharm stock appears to be undervalued.
The current stock price of HK$0.28 is trading 45.1% below its estimated GF Value™ of HK$0.51.
GuruFocus considers PuraPharm to be Possible Value Trap.
Key valuation signals for HKSE:01498:
EV-to-FCF: 18.87 (56% above median its 10-year median of 12.08)
GF Value™: HK$0.51 vs. price of HK$0.28 (45.1% below fair value)
Industry Position: 11.3% below the Drug Manufacturers median (#256 of 558)
No single metric tells the full story. See the HKSE:01498 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PuraPharm Corporation Ltd is an investment holding company. Along with its subsidiaries, it is engaged in the research, development, production, and sale of concentrated Chinese medicine granules (CCMG) and other Chinese healthcare products. Its operations also include the cultivation and trading of raw Chinese herbs, the manufacture and sale of traditional Chinese medicine (TCM) decoction pieces, and the provision of Chinese medical diagnostic services. The Group's reportable operating segments are: China CCMG, Hong Kong CCMG, Chinese healthcare products, Clinics, and Plantation. Maximum revenue is derived from the Hong Kong CCMG segment. Geographically, the Group generates maximum revenue from Hong Kong, and the rest from the Chinese Mainland and other countries.
23GF Score
Get the complete analysis for HKSE:01498
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:01498 has been successfully added to your 
